Novartis launches Coartem Baby malaria treatment for newborns and young infants
NVS•Novartis launched Coartem Baby, a malaria treatment designed for newborns and young infants, with approval in 16 countries. Its next-generation antimalarial KLU156 received priority review after submissions to Swissmedic and the U.S. Food and Drug Administration were completed.
1. Treatment launch
Novartis launched Coartem Baby, described as the first malaria treatment designed for newborns and young infants, with approval in 16 countries. Next-generation antimalarial KLU156 received priority review following completed submissions to Swissmedic and the U.S. Food and Drug Administration.
